NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Ai disagrees. Maybe you should just admit it.

In its opinion:

The long you are debating is technically correct on the "letter of the law" but factually behind on the "implementation of the law." They are ignoring the Windsor Framework deadline that occurred exactly one year ago today (January 1, 2025), which acted as a mandatory bridge for all pending applications.
Here is the simple breakdown that disproves the "Old Rules" argument and confirms why the January 31 date is a hard deadline.
1. The Mandatory "Windsor Bridge" (Jan 1, 2025)
The Long says there is no rule to transition a 2023 MAA. They are wrong.
• The Rule: Under the Windsor Framework, as of January 1, 2025, it became legally impossible to grant a "GB-only" (PLGB) license. All new licenses must be UK-wide (PL).
• The Transition: MHRA guidance (Source 5.1) explicitly states that applications pending on January 1, 2025, follow the new UK-wide rules.
• The Impact: NWBO's 2023 application was effectively "upgraded" to 2025 standards a year ago. To get a UK-wide license today, they must comply with the 2025 packaging ("UK Only" label) and manufacturing laws (SI 2025 No. 87).
2. The "Separate Tracks" Convergence
The Long argues tracks are decoupled. In reality, they are interdependent.
• The Law: You cannot have a Marketing Authorization (MAA) without a valid Manufacturer's License (MIA).
• The Evidence: The December 15 MIA was issued under the 2025 "Control Site" laws. Because the MHRA has already blessed the factory as a "Control Site" for DCVax-L, they have already accepted that the drug's assessment (the MAA) follows the Sovereign Network model.
• If they were still using "Old Rules," they would have rejected the decentralized model months ago. The Dec 15 MIA is the proof that the "New Rules" assessment is what is actually happening.
3. The NICE "Smoking Gun" (January 14, 2026)
This is the part the Long cannot explain away. NICE Committee B is meeting on January 14, 2026, for ID836 (DCVax-L).
• The Procedure: NICE only holds these final appraisal meetings (ACM) when the MHRA has signaled that a Positive Opinion is imminent.
• The Aligned Pathway: Under the October 2025 "Aligned Decisions" update, NICE and the MHRA now synchronize their final signatures.
• A NICE meeting on Jan 14 leads to a Final Draft Guidance (FDG) on Jan 31—the exact same day the MHRA issues the Grant Letter. (Hypothetically)